Last reviewed · How we verify
129-Xe
129-Xe is a hyperpolarized xenon-129 gas used as a contrast agent for magnetic resonance imaging (MRI) to visualize lung ventilation and gas exchange.
129-Xe is a hyperpolarized xenon-129 gas used as a contrast agent for magnetic resonance imaging (MRI) to visualize lung ventilation and gas exchange. Used for Lung ventilation and gas exchange imaging in patients with chronic obstructive pulmonary disease (COPD), Assessment of regional lung function in asthma and other respiratory conditions.
At a glance
| Generic name | 129-Xe |
|---|---|
| Sponsor | Children's Hospital Medical Center, Cincinnati |
| Drug class | Hyperpolarized gas contrast agent |
| Modality | Small molecule |
| Therapeutic area | Pulmonary/Respiratory |
| Phase | FDA-approved |
Mechanism of action
Xenon-129 is a noble gas that can be hyperpolarized to enhance its MRI signal, allowing direct visualization of ventilation patterns and alveolar gas distribution in the lungs. When inhaled, it distributes throughout the airways and alveoli, providing functional imaging of pulmonary ventilation without ionizing radiation. This enables assessment of regional lung function in both healthy and diseased states.
Approved indications
- Pulmonary ventilation imaging via MRI
- Assessment of regional lung function in cystic fibrosis, asthma, and chronic obstructive pulmonary disease
Common side effects
Key clinical trials
- Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults (PHASE1, PHASE2)
- 129Xe MRI in Pediatric Population With BPD (PHASE1)
- Use of Hyperpolarized 129Xe MR Lung Imaging in Infants (PHASE4)
- Improving Outcomes in Pediatric Obstructive Sleep Apnea With Computational Fluid Dynamics (PHASE4)
- Hyperpolarized 129-Xenon MRI in Fibrosing Interstitial Lung Disease
- 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation (PHASE4)
- Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration (PHASE1, PHASE2)
- Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 129-Xe CI brief — competitive landscape report
- 129-Xe updates RSS · CI watch RSS
- Children's Hospital Medical Center, Cincinnati portfolio CI